United Therapeutics Corporation $UTHR Shares Acquired by Seizert Capital Partners LLC

Seizert Capital Partners LLC boosted its position in United Therapeutics Corporation (NASDAQ:UTHR) by 2.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 125,541 shares of the biotechnology company’s stock after acquiring an additional 3,571 shares during the quarter. Seizert Capital Partners LLC’s holdings in United Therapeutics were worth $36,074,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in UTHR. HB Wealth Management LLC increased its holdings in United Therapeutics by 2.9% in the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 35 shares during the last quarter. Park Avenue Securities LLC increased its holdings in shares of United Therapeutics by 1.7% in the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock valued at $676,000 after acquiring an additional 39 shares during the last quarter. Applied Finance Capital Management LLC raised its position in shares of United Therapeutics by 3.7% during the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company’s stock worth $349,000 after acquiring an additional 40 shares in the last quarter. Headlands Technologies LLC lifted its stake in United Therapeutics by 1.5% during the first quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company’s stock worth $828,000 after purchasing an additional 40 shares during the last quarter. Finally, First Financial Bankshares Inc boosted its holdings in United Therapeutics by 0.3% in the first quarter. First Financial Bankshares Inc now owns 13,769 shares of the biotechnology company’s stock valued at $4,245,000 after purchasing an additional 42 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $476.59 on Wednesday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $485.32. The stock has a market capitalization of $20.52 billion, a price-to-earnings ratio of 18.06, a PEG ratio of 4.96 and a beta of 0.77. The company has a 50-day simple moving average of $435.39 and a 200-day simple moving average of $352.54.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter in the previous year, the firm posted $6.39 EPS. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research report on Thursday, November 13th. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a report on Wednesday. Royal Bank Of Canada lifted their target price on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. HC Wainwright upped their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, UBS Group raised their price target on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $505.00.

Insider Activity

In other news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 522,935 shares of company stock valued at $224,478,747 over the last quarter. Insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.